Clinical trials: Central Nervous System
- Condition Central Nervous System
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Alzheimer Disease, Cognition Disorder
Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics
The SAD design of the study is based on the aim to study safety, tolerability and PK of selected doses of ACD856 in a limited number of healthy volunteers. ACD856 will be administered orally.
- Trial name
- NCT05077631
- Testing
- ACD856, ACD856 (fed cohort)
- Where
- Sweden
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Muscular Atrophy, Spinal
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
This is a multi-center, open-label, non-randomized, parallel-group, 2-part study to evaluate the effect of hepatic impairment on the PK and safety and tolerability of a single oral dose of risdiplam compared to matched healthy…
- Trial name
- NCT03920865
- Testing
- Risdiplam
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Pain
Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
The purpose of this study is to evaluate the efficacy and safety of diclofenac diethylamine 2.32 percent (%) gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily for 7 days in participants…
- Trial name
- NCT04052620
- Testing
- Diclofenac diethylamine 2.32% gel, Diclofenac diethylamine 1.16% gel
- Where
- 14 sites in China
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Positron Emission Tomography Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
The purpose of this study is to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
- Trial name
- NCT07655518
- Testing
- BMS-986521
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects, Apathy
Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers
This is a phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers.
- Trial name
- NCT06699628
- Testing
- IRL757
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Integrative Research Laboratories AB
Encephalitis, Tick-Borne
Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children
The purpose of this study is to evaluate the safety, immunogenicity and tolerability of TBE vaccines administered to children.
- Trial name
- NCT00311441
- Testing
- Tick-Borne Encephalitis vaccine
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Novartis
Alzheimer Disease
Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production
This is a Phase I, single center, open label, multiple dose, pharmacokinetic (PK) study recruiting healthy older subjects.
- Trial name
- NCT04268953
- Testing
- Tricaprilin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cerecin
Diphtheria, Tetanus
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722). The objectives are: To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01444781
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Parkinson's Disease
Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)
The overall goal of this research proposal is to develop an adjunct to standard treatments that 'correct' disrupted neural circuitry in Parkinson's Disease (PD) patients.
- Trial name
- NCT02922530
- Testing
- Computerized Plasticity-based Adaptive Cognitive Training, Commercially available computerized training
- Volunteers
- healthy volunteers welcome
- Sponsor
- Posit Science Corporation
Huntington Disease, Tardive Dyskinesia
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT05238701
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Epilepsy, Healthy Volunteer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
- Trial name
- NCT07051629
- Testing
- SIF001
- Where
- 10 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Suninflam Inc
Abuse Potential Study
Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users
This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem
- Trial name
- NCT01987739
- Testing
- 200 mg almorexant, 400 mg almorexant, 1000 mg almorexant
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Midnight Pharma, LLC
Alzheimer's Disease
Study Evaluating Safety, Tolerability, Pharmacokinetics and 5 HT1A Receptor Occupancy
The study will include a preliminary pharmacokinetics (PK) / safety / tolerability evaluation in healthy elderly subjects followed by the Receptor Occupancy (RO) evaluations in healthy elderly subjects and in Alzheimer's Disease…
- Trial name
- NCT00499200
- Testing
- SRA-444
- Where
- Sweden
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pain
Efficacy and Safety of DEC103 in Pain Control Associated to Intrauterine Device (IUD) Insertion
The purpose of this study is to evaluate the efficacy and safety of DEC103 in the pain control associated with IUD insertion in women with 18 to 49 years.
- Trial name
- DEC103 (NCT05800392)
- Testing
- DEC103
- Where
- Brazil
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- EMS
Diphtheria, Tetanus
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Objectives: To present the rates of adverse reactions after a dose of DAPTACEL® vaccine administered to children 4 to 6 years of age who have previously received four doses of PENTACEL™ vaccine.
- Conditions
- Diphtheria, Tetanus, Pertussis, Polio
- Trial name
- NCT00802867
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
- Where
- 19 sites in United States
- Volunteers
- 989 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pain
A Trial of HRS4800 Tables in Healthy Male Subjects
This is a single-site study to evaluate the safety, tolerability and pharmacokinetics (PK) of single dose administration of HRS4800, and the effect of food on the PK of HRS4800 in healthy male subjects.
- Trial name
- NCT04573036
- Testing
- HRS4800 tablets
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Pain
Pharmacokinetics, Bioavailability and Safety of PENNSAID® Gel
It is anticipated that PENNSAID Gel will minimize systemic exposure versus oral diclofenac administered twice a day (BID). In addition, PENNSAID Gel should result in greater subject convenience and compliance with a comparable…
- Trial name
- NCT01202799
- Testing
- 2% w/w diclofenac sodium topical gel, 1.5% w/w diclofenac sodium topical solution, 75 mg diclofenac sodium delayed release tablet
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
Aneurysmal Subarachnoid Hemorrhage
Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages
Aneurysmal subarachnoid hemorrhage (aSAH) is a dreadful acute neurological condition with overwhelmingly high rate of associated morbidities and mortality.
- Trial name
- HASH (NCT06548477)
- Testing
- Human albumin
- Where
- Qatar
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Hamad Medical Corporation
Alzheimer Disease
Multiple Dose Japanese Bridging Study
The purpose of this study is to assess the safety and tolerability of multiple oral daily doses of BMS-708163 in healthy young male subjects
- Trial name
- NCT01057030
- Testing
- BMS-708163
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb